Mechanisms of Bile Secretion

Zakim and Boyer's Hepatology

Volumn , Issue , 2012, Pages 47-63

  Jansen, Peter L M ^a   Beuers, Ulrich ^b   Elferink, Ronald P J Oude ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882515159     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0881-3.00004-8     Document Type: Chapter

References (298)

1. Rappaport AM The structural and functional unit in the human liver (liver acinus). Anat Rec 1958, 130(4):673-689.
2. Lamers WH, et al. Hepatic enzymic zonation: a reevaluation of the concept of the liver acinus. Hepatology 1989, 10(1):72-76.
3. Theise ND, et al. The canals of Hering and hepatic stem cells in humans. Hepatology 1999, 30(6):1425-1433.
4. Gatmaitan Z, et al. Studies on fenestral contraction in rat liver endothelial cells in culture. Am J Pathol 1996, 148(6):2027-2041.
5. Bhunchet E, Fujieda K Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology 1993, 18(6):1450-1458.
6. Hardison WG, et al. Function of rat hepatocyte tight junctions: studies with bile acid infusions. Am J Physiol 1991, 260(1 Pt 1):G167-G174.
7. Mitic LL, Van Itallie CM, Anderson JM Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 2000, 279(2):G250-G254.
8. Anderson JM Leaky junctions and cholestasis: a tight correlation. Gastroenterology 1996, 110(5):1662-1665.
9. Hayakawa T, et al. DBcAMP stimulates vesicle transport and HRP excretion in isolated perfused rat liver. Am J Physiol 1990, 259(5 Pt 1):G727-G735.
10. Zegers MM, Zaal KJ, Hoekstra D Functional involvement of proteins, interacting with sphingolipids, in sphingolipid transport to the canalicular membrane in the human hepatocytic cell line, HepG2?. Hepatology 1998, 27(4):1089-1097.
11. Keppler D, Konig J Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis 2000, 20(3):265-272.
12. Kullak-Ublick GA, et al. Hepatic transport of bile salts. Semin Liver Dis 2000, 20(3):273-292.
13. Jones AL, et al. Autoradiographic evidence for hepatic lobular concentration gradient of bile acid derivative. Am J Physiol 1980, 238(3):G233-G237.
14. Groothuis GM, et al. Autoradiographic and kinetic demonstration of acinar heterogeneity of taurocholate transport. Am J Physiol 1982, 243(6):G455-G462.
15. Goodwin B, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000, 6(3):517-526.
16. Ugele B, et al. Heterogeneity of rat liver parenchyma in cholesterol 7 alpha-hydroxylase and bile acid synthesis. Biochem J 1991, 276(Pt 1):73-77.
17. Marzioni M, et al. Functional heterogeneity of cholangiocytes. Semin Liver Dis 2002, 22(3):227-240.
18. Gurantz D, et al. Hypercholeresis induced by unconjugated bile acid infusion correlates with recovery in bile of unconjugated bile acids. Hepatology 1991, 13(3):540-550.
19. Ballatori N, et al. Biliary catabolism of glutathione and differential reabsorption of its amino acid constituents. Am J Physiol 1988, 254(1 Pt 1):G1-G7.
20. Park HZ, Lee SP, Schy AL Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 1991, 100(6):1665-1670.
21. Walters HC, et al. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol 2000, 279(6):G1188-G1200.
22. Dawson PA, et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005, 280(8):6960-6968.
23. Voshol PJ, et al. Postprandial chylomicron formation and fat absorption in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 2000, 118(1):173-182.
24. Van der Veere CN, et al. Oral calcium phosphate: a new therapy for Crigler-Najjar disease?. Gastroenterology 1997, 112(2):455-462.
25. Cuperus FJ, et al. Acceleration of the gastrointestinal transit by polyethylene glycol effectively treats unconjugated hyperbilirubinemia in Gunn rats. Gut 2010, 59(3):373-380.
26. Uyama N, Geerts A, Reynaert H Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 2004, 280(1):808-820.
27. Glaser SS, et al. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009, 11:e7.
28. Stieger B, et al. In situ localization of the hepatocytic Na+/taurocholate cotransporting polypeptide in rat liver. Gastroenterology 1994, 107(6):1781-1787.
29. Hagenbuch B, Scharschmidt BF, Meier PJ Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem J 1996, 316(Pt 3):901-904.
30. Hagenbuch B, Meier PJ Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin Liver Dis 1996, 16(2):129-136.
31. Denson LA, et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001, 121(1):140-147.
32. Jung D, et al. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am J Physiol Gastrointest Liver Physiol 2004, 286(5):G752-G761.
33. Eloranta JJ, Jung D, Kullak-Ublick GA The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 2006, 20(1):65-79.
34. Mukhopadhayay S, et al. cAMP increases liver Na+-taurocholate cotransport by translocating transporter to plasma membranes. Am J Physiol 1997, 273(4 Pt 1):G842-G848.
35. Schonhoff CM, et al. Rab4 facilitates cyclic adenosine monophosphate-stimulated bile acid uptake and Na+-taurocholate cotransporting polypeptide translocation. Hepatology 2008, 48(5):1665-1670.
36. Geier A, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 2005, 289(5):G831-G841.
37. Schonhoff CM, et al. PKCε-dependent and -independent effects of taurolithocholate on PI3K/PKB pathway and taurocholate uptake in HuH-NTCP cell line. Am J Physiol Gastrointest Liver Physiol 2009, 297(6):G1259-G1267.
38. Konig J, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006, 372(6):432-443.
39. Smith NF, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007, 81(1):76-82.
40. Jung D, Kullak-Ublick GA Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003, 37(3):622-631.
41. Keitel V, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005, 41(5):1160-1172.
42. Oswald M, et al. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001, 21(4):247-253.
43. Zollner G, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003, 38(6):717-727.
44. Zollner G, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001, 33(3):633-646.
45. Link E, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. New Engl J Med 2008, 359(8):789-799.
46. Nozawa T, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005, 33(3):434-439.
47. Koepsell H Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 2004, 25(7):375-381.
48. Zhang L, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997, 51(6):913-921.
49. Dean M, Rzhetsky A, Allikmets R The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11(7):1156-1166.
50. Gerloff T, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998, 273(16):10046-10050.
51. Strautnieks SS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998, 20(3):233-238.
52. Jansen PL, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999, 117(6):1370-1379.
53. Wang R, et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc Natl Acad Sci USA 2001, 98(4):2011-2016.
54. Wang R, et al. Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology 2009, 50(3):948-956.
55. Vos TA, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 1998, 28(6):1637-1644.
56. Lee JM, et al. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 2000, 118(1):163-172.
57. Trauner M, et al. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest 1998, 101(10):2092-2100.
58. Vos TA, et al. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology 1999, 29(6):1833-1839.
59. Gerloff T, et al. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. Gastroenterology 1999, 117(6):1408-1415.
60. Zollner G, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001, 33(3):633-646.
61. Zollner G, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003, 38(6):717-727.
62. Ananthanarayanan M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276(31):28857-28865.
63. Claudel T, et al. The farnesoid X receptor: a novel drug target?. Expert Opin Investig Drugs 2004, 13(9):1135-1148.
64. Leveille-Webster CR, Arias IM The biology of the P-glycoproteins. J Membr Biol 1995, 143(2):89-102.
65. Schinkel AH, et al. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995, 96(4):1698-1705.
66. Sharom FJ, et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 1999, 58(4):571-586.
67. Muller M, et al. ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett 1994, 343(2):168-172.
68. Borst P, Schinkel AH Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 1997, 13(6):217-222.
69. Schinkel AH, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77(4):491-502.
70. Mauad TH, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994, 145(5):1237-1245.
71. Schinkel AH, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997, 94(8):4028-4033.
72. Eichelbaum M, Fromm MF, Schwab M Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004, 26(2):180-185.
73. Thottassery JV, et al. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997, 94(20):11037-11042.
74. Zhou G, Kuo MT Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem 1998, 273(25):15387-15394.
75. Ros JE, et al. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology 2001, 33(6):1425-1431.
76. Synold TW, Dussault I, Forman BM The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001, 7(5):584-590.
77. Smit JJ, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994, 71(5):638-649.
78. Smit JJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75(3):451-462.
79. Oude Elferink RP, Groen AK Mechanisms of biliary lipid secretion and their role in lipid homeostasis. Semin Liver Dis 2000, 20(3):293-305.
80. Crawford JM, et al. Imaging biliary lipid secretion in the rat: ultrastructural evidence for vesiculation of the hepatocyte canalicular membrane. J Lipid Res 1995, 36(10):2147-2163.
81. Oude Elferink RP, et al. Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein. J Lipid Res 1996, 37(5):1065-1075.
82. Muller M Transcriptional control of hepatocanalicular transporter gene expression. Semin Liver Dis 2000, 20(3):323-337.
83. Kok T, et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003, 369(Pt 3):539-547.
84. Frijters CM, et al. Regulation of mdr2 P-glycoprotein expression by bile salts. Biochem J 1997, 321(Pt 2):389-395.
85. Huang L, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003, 278(51):51085-51090.
86. Paulusma CC, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271(5252):1126-1128.
87. Lankisch TO, et al. Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008, 17(3):695-701.
88. de Jong FA, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007, 271(5252):1126-1128.
89. Jansen PL, Peters WH, Lamers WH Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985, 5(4):573-579.
90. Kast HR, et al. Regulation of multidrug resistance-associated protein 2 (MRP2;ABCC2) by the nuclear receptors PXR, FXR, and CAR. J Biol Chem 2002, 277(4):2908-2915.
91. Tanaka T, et al. The human multidrug resistance protein 2 gene: functional characterization of the 5′-flanking region and expression in hepatic cells. Hepatology 1999, 30(6):1507-1512.
92. Lee J, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001, 121(6):1473-1484.
93. Ogawa K, et al. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000, 278(3):G438-G446.
94. Donner MG, Keppler D Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001, 34(2):351-359.
95. Soroka CJ, et al. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001, 33(4):783-791.
96. Konig J, et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999, 29(4):1156-1163.
97. Johnson BM, et al. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 2006, 34(4):556-562.
98. Kubo K, Sekine S, Saito M Compensatory expression of MRP3 in the livers of MRP2-deficient EHBRs is promoted by DHA intake. Biosci Biotechnol Biochem 2009, 73(11):2432-2438.
99. Hirohashi T, et al. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 1998, 53(6):1068-1075.
100. Guo GL, et al. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 2003, 278(46):45062-45071.
101. Rius M, et al. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38(2):374-384.
102. Assem M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004, 279(21):22250-22257.
103. Folmer DE, Elferink RP, Paulusma CC P4 ATPases-lipid flippases and their role in disease. Biochim Biophys Acta 2009, 1791(7):628-635.
104. Zachowski A Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J 1993, 294(Pt 1):1-14.
105. Paulusma CC, et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006, 44(1):195-204.
106. Nibbering CP, et al. Regulation of biliary cholesterol secretion is independent of hepatocyte canalicular membrane lipid composition: a study in the diosgenin-fed rat model. J Hepatol 2001, 35(2):164-169.
107. Oude Elferink RP, Paulusma CC, Groen AK Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006, 130(3):908-925.
108. Ujhazy P, et al. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 2001, 34(4 Pt 1):768-775.
109. Paulusma CC, et al. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 2008, 47(1):268-278.
110. Cai SY, et al. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 2009, 136(3):1060-1069.
111. Paulusma CC, et al. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem 2009, 284(15):9947-9954.
112. van der Velden LM, et al. Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 2010, 51(1):286-296.
113. Folmer DE, et al. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology 2009, 50(5):1597-1605.
114. Berge KE, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290(5497):1771-1775.
115. Lu K, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001, 69(2):278-290.
116. Berge KE, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290(5497):1771-1775.
117. Tauscher A, Kuver R ABCG5 and ABCG8 are expressed in gallbladder epithelial cells. Biochem Biophys Res Commun 2003, 307(4):1021-1028.
118. Repa JJ, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002, 277(21):18793-18800.
119. Plosch T, et al. Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice. Am J Physiol Gastrointest Liver Physiol 2006, 291(3):G414-G423.
120. Freeman LA, et al. The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter. J Lipid Res 2004, 45(7):1197-1206.
121. Sumi K, et al. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol 2007, 27(12):4248-4260.
122. Belamarich PF, et al. Response to diet and cholestyramine in a patient with sitosterolemia. Pediatrics 1990, 86(6):977-981.
123. Kosters A, et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol 2003, 38(6):710-716.
124. Vrins C, et al. The sterol transporting heterodimer ABCG5/ABCG8 requires bile salts to mediate cholesterol efflux. FEBS Lett 2007, 581(24):4616-4620.
125. Small DM Role of ABC transporters in secretion of cholesterol from liver into bile. Proc Natl Acad Sci USA 2003, 100(1):4-6.
126. Bodzioch M, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999, 22(4):347-351.
127. Brewer HB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004, 24(10):1755-1760.
128. Groen AK, et al. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest 2001, 108(6):843-850.
129. Higuchi H, Gores GJ Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 2003, 284(5):G734-G738.
130. Schoemaker MH, et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol 2003, 39(2):153-161.
131. Streetz K, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000, 119(2):446-460.
132. Ghose R, et al. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2004, 2(1):4.
133. Wan YJ, et al. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 2000, 20(12):4436-4444.
134. Makishima M, et al. Identification of a nuclear receptor for bile acids. Science 1999, 284(5418):1362-1365.
135. Shih DQ, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001, 27(4):375-382.
136. Lu TT, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000, 6(3):507-515.
137. Sinal CJ, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102(6):731-744.
138. Gartung C, et al. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996, 110(1):199-209.
139. Inagaki T, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2(4):217-225.
140. Schaap FG, et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49(4):1228-1235.
141. Trauner M, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997, 113(1):255-264.
142. Schuetz EG, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001, 276(42):39411-39418.
143. Thompson R, Jansen PL Genetic defects in hepatocanalicular transport. Semin Liver Dis 2000, 20(3):365-372.
144. Bull LN, et al. Fine-resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC. Hum Genet 1999, 104(3):241-248.
145. De Vree JM, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998, 95(1):282-287.
146. Lamireau T, et al. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004, 41(6):920-925.
147. Mosser J, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 1994, 3(2):265-271.
148. Paulusma CC, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997, 25(6):1539-1542.
149. Kartenbeck J, et al. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996, 23(5):1061-1066.
150. Shroyer NF, et al. The rod photoreceptor ATP-binding cassette transporter gene, ABCR, and retinal disease: from monogenic to multifactorial. Vision Res 1999, 39(15):2537-2544.
151. Brooks-Wilson A, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999, 22(4):336-345.
152. Otonkoski T, et al. A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 1999, 48(2):408-415.
153. Ringpfeil F, et al. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 2000, 97(11):6001-6006.
154. Bull LN, et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997, 26(1):155-164.
155. Klomp LW, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 2004, 40(1):27-38.
156. Oshima T, Ikeda K, Takasaka T Sensorineural hearing loss associated with Byler disease. Tohoku J Exp Med 1999, 187(1):83-88.
157. Stapelbroek JM, et al. ATP8B1 is essential for maintaining normal hearing. Proc Natl Acad Sci USA 2009, 106(24):9709-9714.
158. Lykavieris P, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003, 39(3):447-452.
159. Chen F, et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004, 126(3):756-764.
160. Bustorff-Silva J, et al. Partial internal biliary diversion through a cholecystojejunocolonic anastomosis-a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report. J Pediatr Surg 2007, 42(8):1337-1340.
161. Melter M, et al. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol 2000, 95(12):3522-3528.
162. Kurbegov AC, et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 2003, 125(4):1227-1234.
163. Egawa H, et al. Intractable diarrhea after liver transplantation for Byler's disease: successful treatment with bile adsorptive resin. Liver Transpl 2002, 8(8):714-716.
164. Tygstrup N, et al. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity. Hepatology 1999, 29(2):506-508.
165. Miyagawa-Hayashino A, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl 2009, 15(6):610-618.
166. Summerskill WH, Walshe JM Benign recurrent intrahepatic "obstructive" jaundice. Lancet 1959, 2:686-690.
167. Floreani A, et al. Autosomal dominant benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24. Am J Med Genet 2000, 95(5):450-453.
168. Brenard R, Geubel AP, Benhamou JP Benign recurrent intrahepatic cholestasis. A report of 26 cases. J Clin Gastroenterol 1989, 11(5):546-551.
169. Cancado EL, et al. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol 1998, 93(9):1510-1517.
170. Balsells F, et al. Benign recurrent intrahepatic cholestasis: improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: a case report. Clin Pediatr (Phila) 1997, 36(8):483-485.
171. Stapelbroek JM, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006, 43(1):51-53.
172. Strautnieks SS, et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am J Hum Genet 1997, 61(3):630-633.
173. van Mil SW, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004, 127(2):379-384.
174. Morton DH, et al. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 2000, 119(1):188-195.
175. Carlton VE, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet 2003, 34(1):91-96.
176. Clayton PT, et al. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy- and 3 beta, 7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. J Clin Invest 1987, 79(4):1031-1038.
177. Jacquemin E, et al. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr 1994, 125(3):379-384.
178. Setchell KD, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998, 102(9):1690-1703.
179. Shneider BL, et al. Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr 1994, 124(2):234-238.
180. Stieger B, et al. Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters. Eur J Biochem 1997, 244(1):39-44.
181. Deleuze JF, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996, 23(4):904-908.
182. Jacquemin E Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 2001, 21(4):551-562.
183. Jacquemin E, et al. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999, 353(9148):210-211.
184. Jacquemin E, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997, 25(3):519-523.
185. Rosmorduc O, et al. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125(2):452-459.
186. Rosmorduc O, Hermelin B, Poupon R MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001, 120(6):1459-1467.
187. Ziol M, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008, 135(1):131-141.
188. Pauli-Magnus C, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004, 39(3):779-791.
189. Geuken E, et al. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J Hepatol 2004, 41(6):1017-1025.
190. Pauli-Magnus C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004, 14(2):91-102.
191. Painter JN, et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 2005, 13(4):435-439.
192. Dixon PH, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000, 9(8):1209-1217.
193. de Pagter AG, et al. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives?. Gastroenterology 1976, 71(2):202-207.
194. Pauli-Magnus C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004, 14(2):91-102.
195. Mazzella G, et al. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001, 33(3):504-508.
196. Palma J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997, 27(6):1022-1028.
197. Aagenaes O Hereditary cholestasis with lymphoedema (Aagenaes syndrome, cholestasis-lymphoedema syndrome). New cases and follow-up from infancy to adult age. Scand J Gastroenterol 1998, 33(4):335-345.
198. Bull LN, et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000, 67(4):994-999.
199. Wada M, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998, 7(2):203-207.
200. Buchler M, et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996, 271(25):15091-15098.
201. Keitel V, et al. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003, 284(1):G165-G174.
202. Ananthanarayanan M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276(31):28857-28865. (Ref.62).
203. Assem M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004, 279(21):22250-22257. (Ref.102).
204. Brewer HB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004, 24(10):1755-1760. (Ref.127).
205. Bustorff-Silva J, et al. Partial internal biliary diversion through a cholecystojejunocolonic anastomosis-a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report. J Pediatr Surg 2007, 42(8):1337-1340. (Ref.160).
206. Cai SY, et al. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 2009, 136(3):1060-1069. (Ref.110).
207. Carlton VE, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet 2003, 34(1):91-96. (Ref.175).
208. Chen F, et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004, 126(3):756-764. (Ref.159).
209. Claudel T, et al. The farnesoid X receptor: a novel drug target?. Expert Opin Investig Drugs 2004, 13(9):1135-1148. (Ref.63).
210. Cuperus FJ, et al. Acceleration of the gastrointestinal transit by polyethylene glycol effectively treats unconjugated hyperbilirubinemia in Gunn rats. Gut 2010, 59(3):373-380.
211. Dawson PA, et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005, 280(8):6960-6968.
212. de Jong FA, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007, 81(1):42-49. (Ref.88).
213. Dean M, Rzhetsky A, Allikmets R The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11(7):1156-1166. (Ref.49).
214. Denson LA, et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001, 121(1):140-147. (Ref.31).
215. Donner MG, Keppler D Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001, 34(2):351-359. (Ref.94).
216. Egawa H, et al. Intractable diarrhea after liver transplantation for Byler's disease: successful treatment with bile adsorptive resin. Liver Transpl 2002, 8(8):714-716. (Ref.163).
217. Eichelbaum M, Fromm MF, Schwab M Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004, 26(2):180-185. (Ref.72).
218. Eloranta JJ, Jung D, Kullak-Ublick GA The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 2006, 20(1):65-79. (Ref.33).
219. Folmer DE, Elferink RP, Paulusma CC P4 ATPases-lipid flippases and their role in disease. Biochim Biophys Acta 2009, 1791(7):628-635. (Ref.103).
220. Folmer DE, et al. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology 2009, 50(5):1597-1605. (Ref.113).
221. Freeman LA, et al. The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter. J Lipid Res 2004, 45(7):1197-1206. (Ref.120).
222. Geier A, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 2005, 289(5):G831-G841. (Ref.36).
223. Geuken E, et al. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J Hepatol 2004, 41(6):1017-1025. (Ref.189).
224. Ghose R, et al. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2004, 2(1):4. (Ref.132).
225. Glaser SS, et al. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009, 11:e7. (Ref.27).
226. Goodwin B, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000, 6(3):517-526. (Ref.15).
227. Groen AK, et al. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest 2001, 108(6):843-850. (Ref.128).
228. Guo GL, et al. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 2003, 278(46):45062-45071. (Ref.100).
229. Higuchi H, Gores GJ Bile acid regulation of hepatic physiology: IV bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 2003, 284(5):G734-G738. (Ref.129).
230. Huang L, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003, 278(51):51085-51090. (Ref.85).
231. Inagaki T, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2(4):217-225. (Ref.139).
232. Jacquemin E Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 2001, 21(4):551-562. (Ref.182).
233. Johnson BM, Zhang P, Schuetz JD, Brouwer KL Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 2006, 34(4):556-562. (Ref.97).
234. Jung D, et al. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am J Physiol Gastrointest Liver Physiol 2004, 286(5):G752-G761. (Ref.32).
235. Jung D, Kullak-Ublick GA Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003, 37(3):622-631. (Ref.40).
236. Kast HR, et al. Regulation of multidrug resistance-associated protein 2 (MRP2;ABCC2) by the nuclear receptors PXR, FXR, and CAR. J Biol Chem 2002, 277(4):2908-2915.
237. Keitel V, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005, 41(5):1160-1172. (Ref.41).
238. Keitel V, et al. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003, 284(1):G165-G174. (Ref.201).
239. Keppler D, Konig J Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis 2000, 20(3):265-272. (Ref.11).
240. Klomp LW, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 2004, 40(1):27-38. (Ref.155).
241. Koepsell H Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 2004, 25(7):375-381. (Ref.47).
242. Kok T, et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003, 369(Pt 3):539-547. (Ref.83).
243. Konig J, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006, 372(6):432-443. (Ref.38).
244. Kosters A, et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol 2003, 38(6):710-716. (Ref.123).
245. Kubo K, Sekine S, Saito M Compensatory expression of MRP3 in the livers of MRP2-deficient EHBRs is promoted by DHA intake. Biosci Biotechnol Biochem 2009, 73(11):2432-2438. (Ref.98).
246. Kullak-Ublick GA, et al. Hepatic transport of bile salts. Semin Liver Dis 2000, 20(3):273-292. (Ref.12).
247. Kurbegov AC, et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 2003, 125(4):1227-1234. (Ref.162).
248. Lamireau T, et al. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004, 41(6):920-925. (Ref.146).
249. Lankisch TO, et al. Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008, 17(3):695-701. (Ref.87).
250. Lee J, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001, 121(6):1473-1484. (Ref.92).
251. Link E, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. New Engl J Med 2008, 359(8):789-799. (Ref.45).
252. Lu K, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001, 69(2):278-290. (Ref.115).
253. Lykavieris P, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003, 39(3):447-452. (Ref.158).
254. Marzioni M, et al. Functional heterogeneity of cholangiocytes. Semin Liver Dis 2002, 22(3):227-240. (Ref.17).
255. Mazzella G, et al. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001, 33(3):504-508. (Ref.195).
256. Mitic LL, Van Itallie CM, Anderson JM Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 2000, 279(2):G250-G254. (Ref.7).
257. Miyagawa-Hayashino A, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl 2009, 15(6):610-618. (Ref.165).
258. Nibbering CP, et al. Regulation of biliary cholesterol secretion is independent of hepatocyte canalicular membrane lipid composition: a study in the diosgenin-fed rat model. J Hepatol 2001, 35(2):164-169. (Ref.106).
259. Nozawa T, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005, 33(3):434-439. (Ref.46).
260. Oswald M, et al. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001, 21(4):247-253. (Ref.42).
261. Oude Elferink RP, Paulusma CC, Groen AK Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006, 130(3):908-925. (Ref.107).
262. Painter JN, et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 2005, 13(4):435-439.
263. Pauli-Magnus C, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004, 39(3):779-791. (Ref.188).
264. Pauli-Magnus C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004, 14(2):91-102. (Refs.190, 194).
265. Paulusma CC, et al. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem 2009, 284(15):9947-9954. (Ref.111).
266. Paulusma CC, et al. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 2008, 47(1):268-278. (Ref.109).
267. Paulusma CC, et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006, 44(1):195-204. (Ref.105).
268. Plosch T, et al. FAbcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice. Am J Physiol Gastrointest Liver Physiol 2006, 291(3):G414-G423. (Ref.119).
269. Repa JJ, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002, 277(21):18793-18800. (Ref.118).
270. Rius M, et al. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38(2):374-384. (Ref.101).
271. Ros JE, et al. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology 2001, 33(6):1425-1431. (Ref.75).
272. Rosmorduc O, et al. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125(2):452-459. (Ref.185).
273. Rosmorduc O, Hermelin B, Poupon R MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001, 120(6):1459-1467. (Ref.186).
274. Schaap FG, et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49(4):1228-1235. (Ref.140).
275. Schoemaker MH, et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol 2003, 39(2):153-161. (Ref.130).
276. Schonhoff CM, et al. Rab4 facilitates cyclic adenosine monophosphate-stimulated bile acid uptake and Na+-taurocholate cotransporting polypeptide translocation. Hepatology 2008, 48(5):1665-1670. (Ref.35).
277. Schonhoff CM, et al. PKCε-dependent and -independent effects of taurolithocholate on PI3K/PKB pathway and taurocholate uptake in HuH-NTCP cell line. Am J Physiol Gastrointest Liver Physiol 2009, 297(6):G1259-G1267. (Ref.37).
278. Schuetz EG, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001, 276(42):39411-39418. (Ref.142).
279. Shih DQ, et al. Hepatocyte nuclear factor-1 alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001, 27(4):375-382. (Ref.135).
280. Small DM Role of ABC transporters in secretion of cholesterol from liver into bile. Proc Natl Acad. Sci USA 2003, 100(1):4-6. (Ref.125).
281. Smith NF, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007, 81(1):76-82. (Ref.39).
282. Soroka CJ, Lee JM, Azzaroli F, Boyer JL Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001, 33(4):783-791. (Ref.95).
283. Stapelbroek JM, et al. ATP8B1 is essential for maintaining normal hearing. Proc Natl Acad Sci USA 2009, 106(24):9709-9714. (Ref.157).
284. Stapelbroek JM, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006, 43(1):51-53. (Ref.171).
285. Sumi K, et al. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol 2007, 27(12):4248-4260. (Ref.121).
286. Synold TW, Dussault I, Forman BM The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001, 7(5):584-590. (Ref.76).
287. Tauscher A, Kuver R ABCG5 and ABCG8 are expressed in gallbladder epithelial cells. Biochem Biophys Res Commun 2003, 307(4):1021-1028. (Ref.117).
288. Ujhazy P, et al. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 2001, 34(4 Pt 1):768-775. (Ref.108).
289. Uyama N, Geerts A, Reynaert H Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 2004, 280(1):808-820. (Ref.26).
290. van der Velden LM, et al. Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 2010, 51(1):286-296. (Ref.112).
291. van Mil SW, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004, 127(2):379-384. (Ref.173).
292. Vrins C, et al. The sterol transporting heterodimer ABCG5/ABCG8 requires bile salts to mediate cholesterol efflux. FEBS Lett 2007, 581(24):4616-4620. (Ref.124).
293. Walters HC, et al. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol 2000, 279(6):G1188-G1200. (Ref.21).
294. Wang R, et al. Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology 2009, 50(3):948-956. (Ref.54).
295. Wang R, et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc Natl Acad Sci USA 2001, 98(4):2011-2016. (Ref.53).
296. Ziol M, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008, 135(1):131-141. (Ref.187).
297. Zollner G, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003, 38(6):717-727. (Refs.43, 61).
298. Zollner G, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001, 33(3):633-646. (Refs.44, 60).